Thank you for your question.
As very well explained by Dr. Quach, the clinical trial data is very robust. When you look at the data that was generated for the AstraZeneca vaccine, you see that 24,000 people were in the clinical trials, and the level of severe adverse events that were identified was no different between the vaccine and the people who got the control, so we have strong data to support the fact that there is no safety concern with the vaccine itself.
There have been reports in Europe of thromboembolic events, and they're investigating them. What will have to be determined by the regulatory authorities is whether or not there's a causal relationship between those situations and the vaccine.